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Search for new chemical structures possessing specific biological activity is a complex problem that needs the use
of the latest achievements of molecular modeling technologies. It is well known that SH2 domains play a major
role in ontogenesis as intermediaries of specific protein-protein interactions. Aim. Developing an algorithm to
investigate the properties of SH2 domain binding, search for new potential active compounds for the whole SH2
domains class.Methods. In this paper, we utilize a complex of computer modeling methods to create a generic
set of potentially active compounds targeting universally at the whole class of SH2 domains. A cluster analysis of all
available three-dimensional structures of SH2 domains was performed and general pharmacophore models
were formulated. The models were used for virtual screening of collection of drug-like compounds provided by
Enamine Ltd. Results. The design technique for library of potentially active compounds for SH2 domains class
was proposed. Conclusions. The original algorithm of SH2 domains research with molecular docking method
was developed. Using our algorithm, the active compounds for SH2 domains were found.
Keywords: molecular modeling, SH2 domains, pharmacophore models, virtual screening.
Introduction. Biological processes in the living system
involve a wide variety of protein molecules interacting
with each other in stable or dynamic protein comple-
xes. The number and variety of protein interactions are
so large and complicated, it makes an extremely comp-
lex and intricate network [1]. Hence, knowledge of the
spatial structure of cellular protein complexes and their
ligands is an important step forward to understanding
the mechanisms of cell functioning.
SH2 domains are mostly contained in the cancer-rela-
ted proteins (e. g. Src oncoprotein) and the proteins which
are parts of cell signaling pathways. Human genome
encodes about 120 SH2 domains which are included in
110 different proteins. They are present in various pro-
tein classes including protein kinases (Src, Lck), phos-
phatases (SHP2, SHIP2), phospholipases (PLC1), trans-
cription factors (STAT), regulatory proteins (SOCS),
adapter proteins (Grb2), structural proteins (SHC) and
others. The widespread presence of SH2 domains in ani-
mals and almost complete absence of them in microor-
ganisms (e. g. primitive SH2 fragments in yeast) may
testify that their appearance is related to complication
of the signal transduction mechanisms in multicellular
organisms [2]. SH2 domain is a compact globular domain
which is actively involved in intracellular signaling path-
ways. It plays an important role in mediating specific
protein-protein interactions [3, 4]. It consists of about
100 amino acids and includes seven-sheets and two-
helices. Its binding site is characterized by a well-defi-
ned placement of ArgB5 which makes a strong hydro-
gen bond with two oxygen atoms of phosphotyrosine
[5]. Also, the binding pocket is characterized by a large
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hydrophobic part, which creates prerequisites for see-
king various selective ligands for this class of domains.
The SH2 domain is the largest class of pTyr-distinctive
domains [6].
Recent research has shown that it is possible to divi-
de SH2 domains according to the specificity of recogni-
tion of pTyr residue with C-terminus. Such recognition
may occur in position +1, +2, and +3 residues in rela-
tion to pTyr [7]. Hence, each SH2 domain binds only to
specific phosphotyrosine-containing fragments. For
example, the Src SH2 domain mostly recognizes Glu-
Glu-Ile (binding fragment pYEEI), whereas the Grb2
SH2 domain binds to another fragment – pYVNV. How-
ever, complete understanding of this effect requires de-
tailed study of thermodynamic peculiarities of the inter-
action between SH2 domains and phosphopeptides.
The main goal of this work is to develop an appro-
priate algorithm to investigate the SH2 domain binding
properties and to make a universal library which poten-
tially could be active to the whole SH2 domain class. A
generic library of ligands for the whole class of SH2
domains may be created by the molecular modeling me-
thods. Such a library may be used for prediction of the
intracellular disturbances, related to the functioning of
SH2 domains and its therapeutic utilization.
Materials and methods. Selection of protein struc-
tures. We have reported the generic SH2 domain cluste-
rization algorithm in detail previously [8]. 1129 three-di-
mensional SH2 binding site structures retrieved from a
Protein Data Bank (PDB) were numerically described
based on the geometric shape of their molecular surface.
Using cluster analysis of the resulting descriptors, 8 diver-
se structures were selected for the virtual screening study.
Preparation of small molecule compound collection.
A collection of drug-like compounds provided by Ena-
mine Ltd. [9] and containinng 1.2 million compounds
was used as an original source of the molecular data. Ta-
king into account that docking requires a lot of resour-
ces, the Enamine base of chemicals was reduced step by
step. Firstly, the Enamine database was reduced to 500
thousand compounds according to the criterion of two-di-
mensional chemical structures. The selected compounds
were used at the second stage for creations of all poss-
ible compound conformations (maximum relative ener-
gy 50 kJ/mol and minimal RMSD (root-mean-square
deviation) of atoms of two conformations 0.4 nm). The
amount of the compounds’ conformation was about 3.5
million. Then, 200 thousand compounds were selected
from them using the pharmacophore properties diversi-
ty represented by piDAPH3 fingerprints (such as char-
ge, donor or acceptors of Hydrogen bond, -bonds). Fi-
nally, using three-dimensional shape of the molecule,
50 thousand compounds were selected.
Virtual screening. Molecular docking (MD) was
performed using a flexible ligand and a fixed receptor
model. We used an algorithm of systematic docking
(SDOCK+) implemented in QXP docking software,
which had shown high reproducing ability of ligand
conformation with minimum RMSD in comparison to
the crystallographic data [10]. The maximum number of
SDOCK+ routine steps was set to 100, and the 10 best
structures (based on built-in QXP scoring function [11])
were retained for each compound. In accordance with
the defined pharmacophore models, the resulting pro-
tein-ligand complex structures had been filtered by in-
trinsic Flo+ filters and multiRMSD software package
[12]. Filtering was based on such criteria as the built-in
QXP scoring function, the number of hydrogen bonds,
the protein-ligand contact surface area and the distance
from ligand to key points of the corresponding pharma-
cophore model.
Results and discussion. Selection of SH2 domain
structures. Based on the SH2 domain-ligand binding
analysis the main points of pharmacophore models we-
re found. So, the main points of those models are the bin-
ding site of the pocket (characterized by the large num-
ber of hydrogen bond donors (Fig. 1, A, B, C (ARG26,
ARG42) and D (ARG524, ARG612)), the center of the
pocket (determined by the oxygen position of the se-
cond amino acid residue (Fig. 1, A, B, C (His63) and D
(His636)) and one or two hydrophobic pockets, which
are located behind the pocket center and generally fil-
led with the hydrophobic part of ligand. Then, using the
cluster analysis of binding site, the shapes of 8 diverse
SH2 domain structures were selected (Table) [8].
Molecular docking. Prior to the docking routine, wa-
ter molecules were removed from the PDB structures.
All Arg and Lys residues were protonated in order to be
capable of forming a large number of hydrogen bonds.
Regardless of the fact that all binding site clusters were
formed within the common framework, particular sets of
rules for ligand selection were defined for each cluster,
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determined by the pTyr-binding site and hydrophobic po-
cket orientation.
A set of 50000 small molecule structures was docked
into the selected SH2 domain binding sites. All possible
stereoisomers were generated resulting in about 125000
three-dimensional structures, subsequently docked into
the binding sites using QXP/Flo software with 100 steps
of SDOCK+ routine. The 10 lowest energy complex struc-
tures were selected for each small molecule, resulting in
a total of about 10 millions of protein-ligand complexes,
which were then filtered by the internal Flo+ filters and
the geometry-based filters [12]. In all cases, we had fol-
lowed the conditions of maximum possible imitation of
phosphotyrosine: the ligand had to fill compactly a volu-
me of phosphotyrosine-binding pocket by creating strong
hydrogen bonds and cation- interaction with the main
amino acid residue. In all cases it was one or two ARG.
So, the general filtering criterion was similar. Exactly this
specific binding site was considered to be the key one for
the target inhibition. 30000 complexes retained after filte-
ring were the subject for visual analysis.
Chemical groups which can mimic phosphotyrosine
and the four main binding models (A, B, C, and D) are de-
picted in Fig. 1. Description of the models follows:
A – the model is characterized by the presence of ad-
ditional hydrogen bonds involving polar radicals of a
phosphotyrosine simulation fragment: hydrogen bonds
formed by Arg26 and Arg46. Additionally, strong bin-
ding to Arg26 occurs through the cation- interaction
with the pyrimidine heterocycle. The ligand also par-
tially fills t Design of potentially active ligands for
SH2 domains by modeling methods he other part of
the subpocket and has ste- ric interactions with Gln30,
Val52 and His63. In this part, the polycycle is
spatially close to Arg61 and the possibility of creation
of cation- interaction exists.
B – the model is characterized by binding the massi-
ve heterocycle core, the volume of which exceeds that
of the phosphotyrosine fragment. The stabilization oc-
curs through the cation- interaction with Arg26 and
hydrogen bonds with Arg42. Almost whole surface of
the tricycle is involved in this process. Formation of
the hydrogen bond between His63 and sulfur dioxide
is important as well, as this bond causes more rigidity
in the protein-ligand binding. Furan fragment adds sta-
bilization to the protein-ligand complex due to Van der
Waals force.
C – the model is characterized by partial filling of
the phosphotyrosine site. Nitrogen-containing hetero-
cycle creates the hydrogen bonds with Arg42 and
Arg26. In this case, the tetrazole fragment, which is a
classical acid group electrostatic simulator, plays the
role of phospho-tyrosine mimetic. The model also an-
ticipates the hardening of peptide binding due to the
formation of another cluster of hydrogen bonds bet-
ween the NH group and His63, which is located in the
other part of the binding pocket but plays an important
role in the binding of peptide substrates. Additionally,
the formation of the steric interactions with Gln67,
Ile65, His63, Phe75 and Phe64 occurs. Owing to the
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Fig. 1. Models of SH2 binding based on the
example of centroids 2KK6 (A, B, C) and 1UUS
(D) (ribbon and surface diagram). Centroid sur-
face is shown as a translucent green skin, the se-
condary structural elements (A (right) and B
(left) helices) of the SH2 domain in red and the
binding site in red. Crucial points which deter-
fact that ligand has flat spatial conformation, it is al-
most completely distributed in the pocket and in both
parts of the site the binding is not complete. Neverthe-
less, the compounds which have been selected from this
model exhibited good inhibitory effect.
D – the model is represented by a centroid, which is
based on PDB record 1UUS. This model has a funda-
mentally different binding mechanism with the amino
acid environment. In this case ligand fills the phospho-
tyrosine binding site and forms strong hydrogen bonds
between Arg594, Arg612 and benzenesulfonamide part
of the ligand. The model involves the second cluster of
hydrogen bonds between pyridine and Arg633, which
is spatially close to the center of the pocket. Moreover,
the significant part of the ligand creates stacking and
cation- interaction with Lys635, His636 and Tyr637.
Thus, the ligand is firmly fixed in the binding site and
shows a significant inhibition effect.
Based on the fact that in all cases the total estimated
free energy of complexation is close to the possible mi-
nimum value (A: –16.0; B: –16.6; C: –19.5 and D: –23.5
kJ/mol), it is too difficult without biological testing to
predict which model is better. Furthermore, in various
tests different model may appear to be better even in
case if biological tests are used (it depends on the SH2
domain used in the test). Thus, our screening has shown
13 active compounds from A, 56 from C and 14 from D
model. Model B did not check out at all. It might be con-
nected with the binding complication between massive
heterocyclic core and small pTyr binding site of the do-
main. The resulting library included 3018 structures,
each containing 20 to 40 atoms. Computer simulations
show that the selected structures form a complex net-
work of chemical interactions in phosphotyrosine bin-
ding pocket and reflect all possible modes of the SH2
domain blocking. This confirms a significant chemical
diversity of the library and high flexibility of the phos-
photyrosine pocket. Moreover, new specific groups able
to imitate pTyr have been detected (Fig. 2). Compari-
son of ADME (absorption, distribution, metabolism
and excretion) (LogP, LogS, PSA, Molweight, HbAcc,
HbDon, RotationBonds) parameters in the initial and fi-
nal databases had been carried out to check representa-
tiveness of the obtained targeted library. As a result, the
difference appeared to be minor. That means the library
possesses full chemical diversity of the initial database
of compounds within the scope of drug-likeness rules.
Nevertheless, a shift of the distribution towards an in-
crease of rotational bonds should be mentioned; this is
not surprising because such molecules are able to obtain
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Centroid: structure (PDB code, chain, model) Organism, protein and domain Number of structures
1o49, chain A Homo sapiens SRC SH2 223
2fci, chain A, model 6 Bos taurus PLCG1 SH2-2 48
2ge9, chain A, model 15 Homo sapiens BTK SH2 72
3in7, chain A Homo sapiens GRB2 SH2 183
2jyq, chain A, model 9 Homo sapiens GRB2 SH2 114
2k7a, chain B, model 5 Mus musculus ITK SH2 218
2kk6, chain A, model 14 Homo sapiens FER SH2 149
1uus, chain A Dictyostelium discoideum DSTA SH2 129
SH2 domain structures selected for MD
Fig. 2. The fragments, which can imitate phosphotyrosine
a large number of diverse conformations, and thus are
more likely to be selected.
Conclusions. This paper presents a few-stage ap-
proach to the creation of universal library for the whole
SH2 domain class. After docking and analysis of its re-
sult, it has been created a general library of the inhibi-
tors mimicking main modes of blocking the binding site
of SH2 domain family. Moreover, specific structural
fragments (e. g. cyclosulfolanic and arylsulfamid groups)
have been identified as pTyr substitutes. Almost in all
cases the ligand tightly fills the phosphotyrosine binding
site and creates hydrogen bonds with the key amino acids
Arg and Lys. Besides, there is a steric interaction bet-
ween ligands and amino acids Glu, Val, Pro, His and Ser.
Äèçàéí ïîòåíö³éíî àêòèâíèõ ðå÷îâèí äëÿ SH2 äîìåí³â ìåòîäàìè
ìîëåêóëÿðíîãî ìîäåëþâàííÿ
Â. Â. Ãóðìà÷, Î. Ì. Áàë³íñüêèé, Ì. Î. Ïëàòîíîâ, Î. Ì. Áîéêî,
Ï. Î. Áîðèñêî, Þ. ². Ïðèëóöüêèé
Ðåçþìå
Ïîøóê íîâèõ õ³ì³÷íèõ ñòðóêòóð, çäàòíèõ âèÿâëÿòè ñïåöèô³÷íó
á³îëîã³÷íó ä³þ, º êîìïëåêñíîþ ïðîáëåìîþ, ùî ïîòðåáóº âèêîðè-
ñòàííÿ ñó÷àñíèõ ìåòîä³â ìîëåêóëÿðíîãî ìîäåëþâàííÿ. Â³äîìî,
ùî SH2 äîìåíè â³ä³ãðàþòü âàæëèâó ðîëü â îíòîãåíåç³ ÿê ïîñåðåä-
íèêè ñïåöèô³÷íèõ á³ëêîâî-á³ëêîâèõ âçàºìîä³é.Ìåòà. Ðîçðîáêà àë-
ãîðèòìó äëÿ äîñë³äæåííÿ âëàñòèâîñòåé çâ’ÿçóâàííÿ SH2 äîìåí³â,
ïîøóê ïîòåíö³éíî àêòèâíèõ ðå÷îâèí äëÿ âñüîãî êëàñó SH2 äîìå-
í³â.Ìåòîäè. Âèêîðèñòàíî êîìïëåêñ ìåòîä³â êîìï’þòåðíîãî ìî-
äåëþâàííÿ äëÿ ñòâîðåííÿ óí³âåðñàëüíîãî ö³ëüîâîãî ñåòó ïîòåíö³é-
íî àêòèâíèõ ðå÷îâèí íà âåñü êëàñ SH2 äîìåí³â. Ïðîâåäåíî êëàñ-
òåðíèé àíàë³ç íàÿâíèõ òðèâèì³ðíèõ ñòðóêòóð SH2 äîìåí³â òà
âèçíà÷åíî çàãàëüí³ ôàðìàêîôîðí³ ìîäåë³, ÿê³ çàñòîñîâàíî äëÿ â³ð-
òóàëüíîãî ñêðèí³íãó êîëåêö³¿ ë³êîïîä³áíèõ ðå÷îâèí ï³äïðèºìñòâà
Enamine. Ðåçóëüòàòè. Çàïðîïîíîâàíî òåõí³êó ïðîåêòóâàííÿ á³á-
ë³îòåêè ïîòåíö³éíî àêòèâíèõ ðå÷îâèí äëÿ êëàñó SH2 äîìåí³â. Âè-
ñíîâêè. Ðîçðîáëåíî îðèã³íàëüíèé àëãîðèòì äîñë³äæåííÿ SH2 äî-
ìåí³â ³ç çàñòîñóâàííÿì ìåòîäó ìîëåêóëÿðíîãî äîê³íãó. Âèêîðèñòî-
âóþ÷è öåé àëãîðèòì, çíàéäåíî àêòèâí³ ðå÷îâèíè äëÿ SH2 äîìåí³â.
Êëþ÷îâ³ ñëîâà: ìîëåêóëÿðíå ìîäåëþâàííÿ, SH2 äîìåíè, ôàðìà-
êîôîðí³ ìîäåë³, â³ðòóàëüíèé ñêðèí³íã.
Äèçàéí ïîòåíöèàëüíî àêòèâíûõ âåùåñòâ äëÿ SH2 äîìåíîâ
ìåòîäàìè ìîëåêóëÿðíîãî ìîäåëèðîâàíèÿ
Â. Â. Ãóðìà÷, À. Ì. Áàëèíñêèé, Ì. Î. Ïëàòîíîâ, À. Í. Áîéêî,
Ï. Î. Áîðèñêî, Þ. È. Ïðèëóöêèé
Ðåçþìå
Ïîèñê íîâûõ õèìè÷åñêèõ ñòðóêòóð, ñïîñîáíûõ ïðîÿâëÿòü ñïåöè-
ôè÷åñêîå áèîëîãè÷åñêîå äåéñòâèå, ÿâëÿåòñÿ êîìïëåêñíîé ïðîáëå-
ìîé, òðåáóþùåé èñïîëüçîâàíèÿ ñîâðåìåííûõ ìåòîäîâ ìîëåêóëÿð-
íîãî ìîäåëèðîâàíèÿ. Èçâåñòíî, ÷òî SH2 äîìåíû èãðàþò âàæíóþ
ðîëü â îíòîãåíåçå êàê ïîñðåäíèêè ñïåöèôè÷åñêèõ áåëêîâî-áåëêî-
âûõ âçàèìîäåéñòâèé. Öåëü. Ðàçðàáîòêà àëãîðèòìà äëÿ èññëåäî-
âàíèÿ ñâîéñòâ ñâÿçûâàíèÿ SH2 äîìåíîâ, ïîèñê ïîòåíöèàëüíî àê-
òèâíûõ âåùåñòâ äëÿ âñåãî êëàññà SH2 äîìåíîâ.Ìåòîäû. Ïðèìå-
íåí êîìïëåêñ ìåòîäîâ êîìïüþòåðíîãî ìîäåëèðîâàíèÿ äëÿ ñîçäà-
íèÿ óíèâåðñàëüíîé öåëåâîé âûáîðêè ïîòåíöèàëüíî àêòèâíûõ âå-
ùåñòâ íà âåñü êëàññ SH2 äîìåíîâ. Ïðîâåäåí êëàñòåðíûé àíàëèç
èìåþùèõñÿ òðåõìåðíûõ ñòðóêòóð SH2 äîìåíîâ è âûäåëåíû îá-
ùèå ôàðìàêîôîðíûå ìîäåëè, èñïîëüçîâàííûå äëÿ ïðîâåäåíèÿ âèð-
òóàëüíîãî ñêðèíèíãà êîëëåêöèè ëåêàðñòâåííî ïîäîáíûõ âåùåñòâ
ïðåäïðèÿòèÿ Enamine. Ðåçóëüòàòû. Ïðåäëîæåíà òåõíèêà ïðî-
åêòèðîâàíèÿ áèáëèîòåêè ïîòåíöèàëüíî àêòèâíûõ âåùåñòâ äëÿ
êëàññà SH2 äîìåíîâ. Âûâîäû. Ðàçðàáîòàí îðèãèíàëüíûé àëãî-
ðèòì èññëåäîâàíèÿ SH2 äîìåíîâ ñ èñïîëüçîâàíèåì ìåòîäà ìîëå-
êóëÿðíîãî äîêèíãà. Ïðèìåíÿÿ ýòîò àëãîðèòì, íàéäåíû àêòèâíûå
âåùåñòâà äëÿ SH2 äîìåíîâ.
Êëþ÷åâûå ñëîâà: ìîëåêóëÿðíîå ìîäåëèðîâàíèå, SH2 äîìåíû,
ôàðìàêîôîðíûå ìîäåëè, âèðòóàëüíûé ñêðèíèíã.
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